Clinical trials: Glioma
Astrocytoma, Glioma
Phase II Study of Irinotecan HCI for Recurrent Anaplastic Astrocytomas, Mixed Malignant Gliomas, and Oligodendrogliomas
Phase 2 trial to explore the efficacy and safety of irinotecan (CPT-11). Also administered at each cycle was zofran/Kytril/Anzemet, decadron, and IV atropine.
- Conditions
- Astrocytoma, Glioma, Oligodendroglioma
- Trial name
- NCT00360828
- Testing
- Irinotecan Hydrochloride (HCI) Treatment, Continued Irinotecan Hydrochloride (HCI) Treatment
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Recurrent Glioblastoma
Study of Pembrolizumab Plus SurVaxM for Glioblastoma at First Recurrence
The main purpose of this study is to assess the clinical activity of Pembrolizumab and SurVaxM in participants with recurrent glioblastoma.
- Trial name
- NCT04013672
- Testing
- Pembrolizumab, SurVaxM, Sargramostim
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- David Peereboom
Glioblastoma, Gliosarcoma
Ph II Bev + Either Temozolomide/Etoposide for GBM Pts Who Have Failed Bev + Irinotecan
Primary objective To estimate 6-month progression free survival probability of pts w recurrent GBM treated w bev + either daily temozolomide/etoposide following progression on bev + irinotecan Secondary Objectives To evaluate…
- Trial name
- NCT00613028
- Testing
- Temo + Avastin, VP-16 + Avastin
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- Duke University
Cancer
Study to Investigate Safety, Pharmacokinetic (PK), Pharmacodynamic (PD) and Clinical Activity of Trametinib in Subjects With Cancer or Plexiform Neurofibromas and Trametinib in Combination With Dabrafenib in Subjects With Cancers Harboring V600 Mutations
This was a 4-part (Part A, Part B, Part C and Part D), Phase I/IIa, multi-center, open label, study in pediatric subjects with refractory or recurrent tumors.
- Trial name
- NCT02124772
- Testing
- Trametinib, Dabrafenib
- Where
- 16 sites in United States, Australia and 3 more
- Volunteers
- 139 people
- Sponsor
- Novartis Pharmaceuticals
Glioma
Comparative Study of Intraoperative MRI-guided vs. Conventional Glioma Surgery
Excision to the maximum possible extent marks the first step of glioma surgery. Depending on tumour histology, adjuvant treatment consists of radio- and/or chemotherapy.
- Trial name
- NCT01394692
- Testing
- intraoperative MRI-guided tumor resection, standard microsurgery
- Where
- Germany
- Volunteers
- 58 people
- Sponsor
- Goethe University
Isocitrate Dehydrogenase Gene Mutation
A Study of HMPL-306 in Advanced Solid Tumors With IDH Mutations
An open label single-arm clinical trial to evaluate the safety, tolerability, PK, PD, and preliminary efficacy of HMPL-306 in advanced or metastatic solid tumors with IDH mutation.
- Trial name
- NCT04762602
- Testing
- HMPL-306
- Where
- 11 sites in United States, Spain
- Volunteers
- 42 people
- Sponsor
- Hutchmed
Brain Tumor
Pilot Study Effect of Sulfasalazine on Glutamate Levels by(Magnetic Resonance Spectroscopy)MRS in Patients With Glioma
The main purpose of this part of the study is to determine the Central Nervous System bioavailability of sulfasalazine.
- Trial name
- NCT01577966
- Testing
- Sulfasalazine
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- University of Alabama at Birmingham
Glioma
Low-dose Temozolomide for 2 Weeks on Brain Tumor Enzyme in Patients With Gliomas (P04602 AM1) (Completed)
The main purpose of this study is to assess the effect of a two-week pre-surgery treatment with low-dose temozolomide (TMZ) on brain tumor methylguanine-DNA (deoxyribonucleic acid) methyltransferase (MGMT) activity in patients…
- Trial name
- NCT00424554
- Testing
- temozolomide
- Volunteers
- 40 people
- Sponsor
- Merck Sharp & Dohme LLC
Malignant Neoplasms of Brain
Vaccine Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
RATIONALE: Vaccines made from a peptide may help the body build an effective immune response to kill tumor cells. Colony-stimulating factors, such as GM-CSF, increase the number of white blood cells and platelets found in bone…
- Trial name
- ACTIVATe (NCT00643097)
- Testing
- PEP-3 vaccine, sargramostim, Temozolomide
- Where
- 2 sites in United States
- Volunteers
- 40 people
- Sponsor
- John Sampson
Glioblastoma Multiforme
Phase II Feasibility Study of Dendritic Cell Vaccination for Newly Diagnosed Glioblastoma Multiforme
Adult patients who have surgical resection of newly diagnosed glioblastoma multiforme will be treated with radiotherapy/chemotherapy followed by dendritic cell vaccine.
- Trial name
- NCT00323115
- Testing
- Autologous Dendritic Cell, Temozolomide, Radiotherapy
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Dartmouth-Hitchcock Medical Center
Glioblastoma Multiforme, Anaplastic Oligoastrocytoma
A Study of Ad-RTS-hIL-12 With Veledimex in Subjects With Glioblastoma or Malignant Glioma
This research study involves an investigational product: Ad-RTS-hIL-12 given with veledimex for production of human IL-12. IL-12 is a protein that can improve the body's natural response to disease by enhancing the ability of the…
- Trial name
- NCT02026271
- Testing
- Ad-RTS-hIL-12, veledimex
- Where
- 6 sites in United States
- Volunteers
- 40 people
- Sponsor
- Alaunos Therapeutics
Glioblastoma
Tivozanib for Recurrent Glioblastoma
This research study is a Phase II clinical trial, which tests the safety and effectiveness of an investigational drug to learn whether the drug works in treating a specific cancer.
- Trial name
- NCT01846871
- Testing
- Tivozanib
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Massachusetts General Hospital
Glioblastoma Multiforme, Glioblastoma
TTFields and Pulsed Bevacizumab for Recurrent Glioblastoma
Glioblastoma multiforme (GBM) is the most common and deadliest primary malignant neoplasm of the central nervous system in adults.
- Conditions
- Glioblastoma Multiforme, Glioblastoma, Malignant Glioma, GBM
- Trial name
- NCT02663271
- Testing
- Bevacizumab, Optune, Brain MRI
- Where
- 2 sites in United States
- Volunteers
- 10 people
- Sponsor
- University of Florida
Advanced Malignant Solid Neoplasm, Glioblastoma
Olaparib in Treating Patients With Advanced Glioma, Cholangiocarcinoma, or Solid Tumors With IDH1 or IDH2 Mutations
This phase II trial studies how well olaparib works in treating patients with glioma, cholangiocarcinoma, or solid tumors with IDH1 or IDH2 mutations that has spread from where it first started (primary site) to other places in…
- Conditions
- Advanced Malignant Solid Neoplasm, Glioblastoma, Recurrent Cholangiocarcinoma, Recurrent Glioma
- Trial name
- NCT03212274
- Testing
- Biopsy Procedure, Biospecimen Collection, Computed Tomography
- Where
- 51 sites in United States
- Volunteers
- 89 people
- Sponsor
- National Cancer Institute (NCI)
Recurrent Childhood Medulloblastoma
Vismodegib in Treating Younger Patients With Recurrent or Refractory Medulloblastoma
This phase II trial studies how well vismodegib works in treating younger patients with recurrent or refractory medulloblastoma. Vismodegib may slow the growth of tumor cells.
- Trial name
- NCT01239316
- Testing
- Laboratory Biomarker Analysis, Pharmacological Study, Vismodegib
- Where
- 12 sites in United States
- Volunteers
- 12 people
- Sponsor
- National Cancer Institute (NCI)
Glioblastoma, Glioblastoma Multiforme
Phase 1/2 Study of Enzastaurin in Newly Diagnosed Glioblastoma Multiforme (GBM) and Gliosarcoma (GS) Patients
There will be 2 phases in this study. Patients will either be enrolled to the first phase or to the second phase, depending upon when they enroll into the study.
- Conditions
- Glioblastoma, Glioblastoma Multiforme, Gliosarcoma
- Trial name
- NCT00402116
- Testing
- enzastaurin, temozolomide, radiation therapy
- Where
- United States
- Volunteers
- 72 people
- Sponsor
- Eli Lilly and Company